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INTRODUCTION 
 
  The recent past has seen an enormous surge in Endoscopic Surgery 
of the Paranasal Sinuses.  The nasal mucosa is rich in blood supply, hence 
impaired visibility ensues owing to excessive bleeding, leading to a 
prolonged surgical time. To avoid such complications, Endoscopic Sinus 
Surgery can be performed either with local anesthesia23, with 
vasoconstrictors (e.g. Epinephrine, Cocaine and Phenylephrine7,17,23), or 
under general anesthesia supplemented with controlled hypotension12.  
Several reports have been recorded regarding various techniques for 
diminishing intraoperative bleeding27,6,14. Many ENT surgeons prefer 
general anesthesia to local anesthesia15,5,9. They are comfortable with 
hypotensive anaesthesia since the duration of surgery is reduced 
considerably with an excellent view of the surgical field. 
 
         Hypotension maybe induced with drugs and volatile anaesthetics 
each having its own advantages and drawbacks. For example., severe 
hypotension may occur due to potent and rapid effects of intravenous 
antihypertensive drugs30.  
 
  Clonidine is a centrally acting α2 agonist useful as a premedicant.  It 
also decreases the need for analgesic consumption and the usage of 
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multiple hypotensive agents intra-operatively. Post operative nausea, 
vomiting and shivering is also reduced.  It has antihypertensive property 
with decreasing sympathetic outflow.  The use of drugs such as oral 
clonidine given before surgery would be desirable to enhance the 
hypotensive action of an inhalation agent without the disadvantages of 
intravenous vasodilators20,21 and the avoidance of polypharmacy.   
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AIM 
 
To analyse oral clonidine given as a premedicant in patients 
undergoing FESS Surgery and its effects; 
1) As a hypotensive agent 
2) On intra operative bleeding using a bleeding severity score. 
3) In maintaining haemodynamic stability intra operatively 
4) Reducing antihypertensive drug requirements 
5) As a premedicant for sedation, intra operative and post operative 
analgesia 
6) To evaluate the side effects and complications if any that may arise 
with the use of clonidine 
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CONTROLLED HYPOTENSION32 
   
  Hypotensive anaesthesia is a technique in which the Blood pressure 
is reduced to the desired level thereby providing the surgeon with a 
bloodless surgical field and minimum blood loss negating the need for 
blood transfusion. The technique entails the controlled lowering of blood 
pressure and is defined as a reduction of the systolic blood pressure to 
between 80-90 mmHg. An alternative definition is a decrease in mean 
arterial pressure (MAP) to 60-70 mmHg in a normotensive patient.  
 
Historical Background 
 
  The concept of intentional induction of hypotension to decrease 
blood loss and improve operative conditions for intracranial surgery was 
first proposed by Cushing in 1917.   Gardner reported on the deliberate 
decrease in blood pressure in patients undergoing difficult neurosurgical 
procedures by arteriotomy.  The blood removed was kept in heparinized 
bottles and reinfused at the end of the procedure. “Irreversible shock,” 
tissure hypoxemia, acidosis and overheparinization indicated that the 
boundaries of physiological trespass were broken down, and the technique 
was quickly abandoned.  Griffiths and Gillies advocated the use of high 
spinal analgesia to induce hypotension.  The major advancement with 
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normovolemic hypotension was achieved when ganglionic blockade was 
combined with foot-down tilt.  Enderby described the new method as 
“controlled circulation with hypotensive drugs and posture to reduce 
bleeding in surgery”.  
 
Ganglionic blocking drugs like Trimethaphan, controlled blood 
pressure by continuous infusion.  Its short action was surpassed only by 
Sodium Nitroprusside (SNP), introduced into clinical practice in 1962.  
The introduction of Halothane allowed an easier and gentler induction of 
hypotension with and without ganglionic blockade.  
 
  β-Adrenergic blocking drugs were introduced to treat tachycardia.  
The 1970s witnessed the introduction of Nitroglycerin and Labetalol as 
hypotensive drugs and the wider use of induced hypotension in pediatric 
surgery.  
 
 Induced Hypotension has also been referred to as deliberate or 
controlled hypotension.   
 
Uses of hypotensive drugs  
 
  Hypotensive drugs are used to achieve one or more of the following 
goals.  
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(i) Reduction of blood loss, 
(ii) Facilitation of vessel surgery, and  
(iii) Improvement of myocardial performance by reducing the preload 
and afterload.  
 
  When hypotensive drugs are used to reduce blood loss, the blood 
pressure is deliberately lowered to hypotensive levels to achieve the 
desired response.  
 
Reduction of blood loss 
 
  By producing a relatively dry operative field, Induced Hypotension 
improves visualization and allows the accurate delineation of lesions. 
There is less trauma inflicted on nerves, vessels, and delicate tissues.  
Hypotension may increase the viability of pedicles and grafts and may 
diminish the incidence of postoperative hematoma, sepsis, and fibrosis.  
There is less need for (or avoidance of) allogenic blood transfusion. In 
certain operations, the need for infiltration with epinephrine (adrenaline) 
containing solution may be eliminated, thereby allowing delicate surgery 
to be performed without distorting the anatomy.  Induced hypotension may 
also decrease operative time.  
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Effects on cardiac output and regional blood flows 
 
  The cardiovascular effects of hypotensive drugs may be modified by 
many factors:  the anesthetic and adjuvant drugs, posture, degree of 
hypotension, intrathoracic pressure, acid-base status, circulating, blood 
volume, age and change in preload and afterload. 
 
(i) Cardiac Output: Vasodilators alter the Cardiac Output through 
changes in stroke volume and heart rate.  They decrease afterload 
lowering arterial impedance and reduce preload by increasing 
venous compliance. 
 
Sodium Nitroprusside -induced hypotension is associated with either 
increased or unchanged Cardiac Output.  In contrast, Nitroglycerin, 
because of its effect on venous capacitance and venous pressure, 
decreases ventricular filling pressure and, ultimately, reduces 
Cardiac Output.  Hypotension secondary to ganglionic blockade has 
variable effects on Cardiac Output. 
 
Induced Hypotension rarely, is followed by organ damage.  As long 
as mean arterial blood pressure exceeds the sum of colloid osmotic 
pressure plus venous pressure, the circulation should be adequate for 
tissue needs. 
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(ii) Coronary circulation: The main factor affecting coronary 
perfusion is the aortic diastolic pressure. During Induced 
Hypotension, reduced myocardial work secondary to decreased 
afterload requires less coronary blood flow.   A decrease in the heart 
rate-systolic pressure product as an index of myocardial oxygen 
demand has been observed during induced hypotension. 
 
(iii) Cerebral Circulation : With progressive decreases in blood 
pressure, a corresponding, decrease occurs in cerebrovascular 
resistance, maintaining normal Cerebral Blood Flow. 
 
Sodium Nitroprusside can abolish cerebral autoregulation and 
increase Cerebral Blood Flow.  Increases in Intra Cranial Pressure 
are mostly seen during the early stages of Sodium Nitroprusside 
infusion, especially during rapid infusion rates.  Hypocapnia tends to 
attenuate SNP-induced increases in Intra Cranial Pressure.  Similar 
increases occur during Nitroglycerin-induced hypotension. In 
contrast Trimethaphan does not usually result in increased Intra 
Cranial Pressure except when intracranial compression is severe. 
 
(iv)  Spinal cord blood flow and function: With the popularity of 
induced hypotension for the operative correction of scoliosis, there 
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has been concern that hypotension may decrease spinal cord blood 
flow and predispose to spinal cord injury, particularly during 
instrumentation. 
 
If deep anesthesia is used during scoliosis surgery, a more prolonged 
time may be needed to successfully perform the wake-up test.  
Furthermore, these higher concentrations of the inhalation anesthetic 
can interfere with SSEP monitoring. 
 
(v) Renal Circulation: Decreases in renal blood flow occur with 
moderate decreases in arterial pressures.  Below 60mmHg (8kPa), 
renal blood flow may decrease to the point where urine flow ceases.  
If Induced Hypotension does not decrease the renal blood flow 
below the critical value for the kidney, it is unlikely that renal 
damage will ensue.  Renal medullar tissue oxygenation, an index of 
tissue viability, remains adequate despite a significant reduction in 
endogenous creatinine clearance during induced hypotension.  Since 
glomerular filtration rate is also not autoregulated during 
anaesthesia, monitoring the urine output may be useful, especially 
during prolonged hypotension. 
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(vi) Hepatic and Regional Blood Flow: A 40% decrease in arterial 
pressure by Sodium Nitroprusside results in a decrease in portal 
pressure (44%) and portal blood flow (25%) and an increase in 
hepatic arterial blood flow (13%).  Sodium Nitroprusside decreases 
portal sinusoidal resistance, does not interfere with the ability of the 
liver to increase hepatic arterial blood flow (in conditions of 
insufficient portal circulation), and does not lead to hepatic hypoxia. 
 
Techniques of Induced Hypotension 
(i) Physiological techniques.  
(ii) Pharmacological agents.  
 
(i) Physiological techniques 
 
  Positioning the patient head up or foot down.  A hypotensive 
response may not be evident in the horizontal position, but subsequent 
tilting decreases the arterial pressure as a result of peripheral venous 
pooling For every 2.5 cm head up tilt there will be a decrease of 2 mm Hg 
reduction in systemic pressure with an increased venous drainage.  The 
patient should not be tilted too quickly as cerebral autoregulation requires 
several minutes. A further decrease in arterial pressure can be obtained by 
a gradual increase in the anesthetic concentration.  
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(ii) Pharmacological agents 
 
Mode of action of hypotensive drugs 
 
Induced hypotension (in normovolemic patients) can be produced by 
either a reduction in Cardiac Output (CO) or a decrease in Systemic 
Vascular Resistance (SVR). The precapillary arterioles contain 
relatively large amounts of amounts of smooth muscle and, thus are 
the major determinants of resistance.  
 
Hypotensive drugs may be classified into: 
(1)    Ganglionic blocking drugs (e.g. Pentolinium, Trimethaphan);  
(2)  Direct-acting vasodilators (e.g. SNP, Nitroglycerin, 
Hydralazine)  
(a) α-adrenergic blocking drugs (e.g. Phentolamine, Urapidil,  
      Nicergoline)  
(b) β-adrenergic blocking drugs (e.g. Propranolol, Esmolol),  
(c) Drugs with combined α-and β-adrenergic blocking actions  
      (e.g. Labetalol)  
(d) Calcium Channel Blocking drugs (e.g. Verapamil,  
      Nicardipine). 
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(1)  Ganglionic blocking drugs.  
 
  Ganglionic blocking drugs compete with acetylcholine for the 
nicotinic receptors on the autonomic post-junctional ganglionic membrane. 
The arterioles and venules of the skin and splanchnic viscera have 
predominantly sympathetic vasoconstrictor innervation, so ganglionic 
blockade produces vasodilation, increased venous capacitance, and 
hypotension.  
 
Side effects: 
 
  Mydriasis and cycloplegia, which may be misinterpreted in the post-
operative neurologic assessment. The Hypotensive action of Trimethaphan 
has been attributed to ganglionic blockade, a direct effect on vascular 
smooth muscle, α-adrenergic blockade, and Histamine release. 
 
(2) Direct-acting vasodilator drugs 
 
Direct-acting vasodilator drugs fall into two categories: 
 
(i) Nitric oxide dependent and  
(ii) Nitric oxide independent.   
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The vasodilating effects of Sodium Nitroprusside and Nitroglycerin 
have been explained by their ability to provide exogenous Nitric oxide.   
 
Sodium Nitroprusside exerts its hypotensive action primarily by 
decreasing Systemic Vascular Resistance whereas the venous effect is 
minimal, so that Cardiac Output is maintained.  In contrast, Nitroglycerin 
has little effect on arteriolar resistance vessels at lower concentrations, but 
exhibits relatively pronounced effects on the venous capacitance vessels, 
which results in decreased venous return, decreased ventricular filling 
pressures, and, ultimately, reduced Cardiac Output. 
 
Hydralazine 
 
  Hydralazine is a direct arteriolar vasodilator.  It decreases blood 
pressure within 10 min by reducing Systemic Vascular Resistance, without 
changing Cardiac Output.  Reflex tachycardia tends to accompany the 
decrease in blood pressure.  The hypotensive effect is more pronounced 
when Hydralazine is given with an inhalation anesthetic. 
 
(a) β-Adrenergic blocking drugs 
 
  Treatment with a β-adrenergic blocking drug prevents the increase 
in heart rate, CO, plasma renin activity, and catecholamine levels and 
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blocks rebound hypertension after cessation of Sodium Nitroprusside 
infusion.  Furthermore, the dose requirements of Sodium Nitroprusside are 
decreased by approximately 40%.  Propranolol given in small increments 
up to 60μg/kg, before or after the hypotensive drug, prevents tachycardia 
and facilitates the control of blood pressure.  
 
  Esmolol-induced hypotension was found to be more effective than 
Sodium Nitroprusside in producing better operative conditions. Because of 
the ability to produce severe myocardial depression, these drugs should 
probably be used as adjuvants rather than as the sole hypotensive agent.  
The advantages of Esmolol are its rapid onset, titration of action, short 
duration, and cardioselectvity.  The drug may be given in a loading dose of 
500μgkg-1 min-1 for 2-4 min and continued by constant infusion  at the rate 
of 300μgkg-1min-1. 
 
(b) Labetalol 
 
  Labetalol acts as a competitive antagonist at bothα1- and β-
adrenergic receptors. 
 
  In patients anesthetized with inhalation anesthetics, Labetalol 
reduces blood pressure gradually (over 5-10 min) by decreasing Systemic 
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Vascular Resistance with either no change in heart rate or with bradycardia 
and a slight or no decrease in Cardiac Output. 
 
  Because of its long elimination half-life (3-6h), it may be the 
preferred drug when prolonged hypotension is required. 
 
  Labetalol is given in an initial dose of 0.2-0.4 mgkg-1.  Incremental 
doses (half the initial dose) may be repeated after 5-10 min until the 
desired hypotension is obtained.  Advantages over Sodium Nitroprusside 
include absence of tachycardia, no increase in Cardiac Output, no rebound 
hypertension, no increase in intrapulmonary shunt, and no increase in Intra 
Cranial Pressure. 
 
(c)  Calcium channel blocking drugs 
 
  Nicardipine and Verapamil exert their hypotensive effects primarily 
by decreasing SVR.  Because Verapamil produces myocardial 
depression and delays atrioventricular conduction, it is not 
recommended for inducing hypotension.  Nicardipine has been 
successfully utilized as a hypotensive drug. It vasodilates the peripheral, 
coronary, and cerebral vessels while maintaining the Cardiac Output 
without tachycardia. Careful titration (10-25μg/kg) is mandatory because it 
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has an “increasing effect” over time and because the hypotension may be 
resistant to conventional treatment. 
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Haemodynamic effects of Hypotensive Drugs: 
 
 
  Sodium Nitroprusside-induced hypotension is associated with 
increases in heart rate, Cardiac Output, activation of the renin-angiotensin 
system, and release of catecholamines.  In contrast, ganglionic blockade 
results in less of an increase in circulating catecholamines and no 
activation of the renin-angiotensin axis.  The increased heart rate with 
ganglionic blocking drugs probably results from parasympathetic 
blockade. 
 
  In response to the initial hypotension, reflex tachycardia, mediated 
through the baroreceptors, occurs with most hypotensive agents, and 
results in an increased Cardiac Output and a rise in blood pressure.  As a 
result of sympathetic activation, renin is released from the juxtaglomerular 
apparatus in the kidney.  This acts on α2-globulin from the liver to produce 
the decapeptide angiotensin I, which is converted in the lungs to the 
octapeptide angiotensin II, a potent vasoconstrictor. 
 
  Stimulation of the sympathetic and the renin-angiotensin systems 
may adversely affect the operative course during hypotension.  The 
increased Cardiac Output can cause bleeding.  Rebound hypertension may 
occur following abrupt termination of the Sodium Nitroprusside infusion.  
This is most likely to be due to an increase in Systemic Vascular 
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Resistance secondary to unopposed activation of the sympathetic and 
renin-angiotensin responses.  The consequences of rebound hypertension 
include wound bleeding, hematoma formation, cerebral edema, 
cerebrovascular accidents, disrupted cerebral autoregulation, increased 
myocardial oxygen demand, and pulmonary edema. 
 
  Very high levels of circulating catecholamine and angiotensin II 
may have deleterious effects on myocardial and renal tubular cells and may 
adversely affect arterial and capillary function. 
 
 Techniques advocated to prevent and treat tachycardia/ 
tachyphylaxis are:  
(i) Judicious use of a β-adrenergic blocking drug.   
(ii) Pretreatment with Saralasin, an angiotensin II competitive 
antagonist, and with Captopril, an oral angiotensin-converting 
enzyme inhibitor.  Pretreatment with Captopril results in lower 
dosage requirements and prevents rebound hypertension.   
(iii) A 10:1 mixture of Trimethaphan (250mg) and SNP (25mg) in a 
solution of 5% Dextrose in water has been advocated.  The mixture 
produces hypotension with smaller doses of SNP and Trimethaphan 
than when either drug is used separately (synergistic effect). 
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(iv) Clonidine, an α2-adrenoceptor agonist, reduces the requirement 
for isoflurane (by 60%) and SNP (by 45%) and substantially 
reduces the need for Labetalol during induced hypotension.  By 
its central effect within the medulla and hypothalamus, 
clonidine blocks the increased central adrenergic activity 
concomitant with the use of hypotensive drugs.  Other actions 
include the inhibition of renin release in the kidney and a 
reduction in Vasopressin release.  The recommended dose is 4-
8μg/kg- given orally 2 hours prior to surgery. 
 
INDICATIONS FOR CONTROLLED HYPOTENSION IN 
ANAESTHESIA 
 
Control of bleeding in major surgeries like 
(1) Major Vascular surgery, Coarctation of Aorta, Arteriovenous fistula, 
Aorto-Pulmonary window and PDA repair. 
(2) Neuro surgery: Intracranial surgery facilitation of intracranial 
exposure because of better visualization and reduction of brain 
volume. 
(3) Liver surgeries like lobectomy and Hepatectomy.  
(4) Oncological surgeries.  
(5) Orthopaedic surgeries. 
(6) Microvascular surgeries. 
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(7) ENT Procedures like FESS, middle ear surgery.  
(8) Adrenal Tumour surgery. 
(9) Inability to replace blood as in Jehovah witness who refuse blood 
transfusion. 
 
CONTRAINDICTIONS 
 
  Relative contraindications to Induced Hypotension include: 
(1)  Pregnancy;  
(2)  Infants where blood pressure is difficult to measure;  
(3)  Children with cardiac shunts; Systemic Vascular Resistance may 
increase the Right to Left shunt and cause hypoxemia;  
(4)  Significant reduction in oxygen delivery; Anemia, low fixed Cardiac 
Output and severe lung disease.   
(5)  Systemic diseases compromising major organ function like: 
- Renal, cerebral, or coronary artery disease;  
(6) Valvular Heart Disease; 
(7) Haematological Disease:  
e.g. (i)  Patients with Sickle cell disease; where a reduction in Pao2 
due  
    to decreased Cardiac Output may trigger a crisis.  
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(ii) Uncorrected Polycythemia may increase sludging and  
      thrombosis; 
(8)  Patients with narrow-angle glaucoma on Ganglionic blocking drugs. 
(9)  Inexperience and unfamiliarity with the technique;  
MONITORING DURING INDUCED HYPOTENSION 
 
(i)  Pulse oximeter. 
(ii)  Invasive & Non-Invasive BP monitoring  
(iii)  Electrocardiography – 12 Lead ECG 
(iv)  Central venous pressure monitoring. 
 (v)  Blood Gas Determination (ABG) for adequacy of oxygenation and 
for metabolic acidosis. 
(vi)  Temperature monitoring 
(vii)  Continuous Urine output monitoring 
 
COMPLICATIONS OF CONTROLLED HYPOTENSION 
 
(i) Severe hypotension / rebound hypertension 
(ii) Reactionary or secondary haemorrhage 
(iii) Delayed haemorrhage after normotension is restored. 
(iv) Blurred vision due to rebound hypertension. 
(v)  Renal disturbance if the blood supply is compromised for a 
prolonged period, it may cause Acute Tubular Necrosis (ATN). 
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(vi)  Thrombic phenomenon following sluggish blood flow in the 
periphery. 
(vii)  Increased intracranial pressure. 
 
  Complications of controlled hypotension can be avoided by inducing 
hypotension in a gradual manner, maintaining a Mean Arterial pressure 
(MAP) above 60 mm Hg and by careful vigilant monitoring methods and 
protocols.  
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CLINICAL PHARMACOLOGY OF ORAL 
CLONIDINE4,10,16 
 
DESCRIPTION  
 
 Clonidine hydrochloride is a centrally acting α2 agonist hypotensive 
agent synthesized in 1960 for intranasal administration and as a nasal 
decongestant. Due to its systemic effects (sedation and hypotension) its use 
as a decongestant has been abandoned. 
 
CHEMISTRY  
 
                 + 
   Cl         H 
       
            N 
 
         N    C    -HCl  
 
           N 
 
   Cl        H  
 
 
  Clonidine hydrochloride is an imidazoline derivative The chemical 
name is (2, 6 – Dichloro – N-2 – imidazolidinylidenebenzenamine 
hydrochloride).  
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  Clonidine hydrochloride is a white crystalline, odorless powder with 
a bitter taste. It is produced by chemical synthesis. It is also available in 
combination with chlorthalidone, triamterene, hydro-chlorothiazide, 
bencyclane fumarate, or cyclothiazide.  
 
PRESENTATION 
 
1. Oral form-100, 200 and 300μg tablets. 
2. Transdermal patch – Delivering Clonidine 100μg, 200μg or 300 μg 
daily for 1 week. 
3. Parenteral form – An aqueous solution containing Clonidine 
Hydrochloride 150μg/ml. in 1 ml ampoules and is intended for slow 
intravenous injection to be given as an adjunct with local anaesthesia 
in regional and neuraxial blocks. 
 
PHARMACOKINETICS 
 
Oral bioavailability     100% 
Plasma protein binding  30 to 40% 
Peak plasma concentration reached in 60 to 90 minutes 
Maximal hypotensive effects 1 to 3 hours after an oral dose. 
Elimination half life 6 to 24 hours. 
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  Approximately 50% of the drug is metabolized in the liver to 
inactive metabolite P-hydroxy-clonidine, while the rest is excreted 
unchanged by the kidneys. About 20% of the total amount is excreted in 
the faeces. 
 
EFFECTS OF ACTION OF CLONIDINE  
 
1. CENTRAL NERVOUS SYSTEM 
 
  Clonidine by virtue of its action on the small discrete nucleus of 
noradrenergic cells in the brainstem, the locus coeruleus causes sedation 
and anxiolysis.  Clonidine is a potent analgesic by itself and acts 
synergistically with concomitant opioids.  Anaesthesia induced by α2 
agonists is mediated through G1 protein and is dependant on inhibitation 
of c-AMP production.  
 
2.  CARDIOVASCULAR SYSTEM  
 
  Action of Clonidine may be classified as (a) peripheral or (b) 
central.  
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(a)  Peripheral  
 
  Clonidine inhibits noradrenaline release from the peripheral 
prejunctional nerve endings and this may lead to bradycardia.  Among the 
different vascular beds the effects of Clonidine on the coronary circulation 
is important.  Clonidine has been documented to release EDRF 
(Endothelial derived relaxant factor) in coronary arteries and to enhance 
coronary blood flow induced by endogenous and exogenous adenosines.  
Intravenous Clonidine causes a transient hypertensive response due to this 
direct action on the post-synaptic α2 receptors.  However this effect is soon 
overcome by a prolonged hypotensive effect due to the more potent 
inhibitory action of Clonidine on central sympathetic outflow.  This effect 
is not seen when Clonidine is administered orally. 
 
(b)  Central 
 
  Clonidine mediated hypotension and bradycardia have been well 
recognized. The mechanism for these actions may involve inhibition of 
sympathetic outflow and the potentiation of parasympathetic nervous 
activity.  However the precise mechanism involved in these actions is not 
well understood.  While the nucleus tractus solitarius is an important 
central site for the action of α2 agonists, other nuclei, including the locus 
coeruleus, the dorsal motor nucleus of vagus and the nucleus of vagus and 
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the nucleus reticularis lateralis may also mediate hypotension, bradycardia 
or both.  It has been documented that the imidazole – preferring receptors 
play an important role in the hypotensive effects of Clonidine. 
 
ANTI – ARRHYTHMIC PROPERTIES 
 
  Clonidine prevents adrenaline – induced arrhythmias during 
Halothane anaesthesia. 
 
3. CEREBRAL CIRCULATION 
 
  Clonidine has been shown to decrease cerebral blood flow.  This 
action may be favourable in protecting the brain from an abrupt increase in 
intracranial tension. 
 
4. RESPIRATORY SYSTEM 
 
Clonidine may produce mild respiratory depression by three mechanisms: 
 
(i)  Sedation or analgesia can produce a small decrease in respiratory 
rate due to anxiolysis or pain relief. 
(ii)  By acting at the α2 receptors close to the respiratory center in the 
brainstem. 
(iii)  By interference of the thermoregulatory control mechanism. 
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Nebulized Clonidine attenuates bronchial constriction in asthmatics. 
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5.  ENDOCRINE SYSTEM 
 
Clonidine can decrease stress induced ACTH release and hence 
cortisol synthesis. 
 
 
  Clonidine activates growth hormone release and hence it has been 
used as a diagnostic tool to test the pituitary gland’s ability to release 
growth factor in children. 
 
  Clonidine also inhibits the release of Insulin from the pancreatic β 
cells directly. 
 
  α2 agonists decrease circulating Norepinephrine and Epinephrine by 
central and peripheral mechanism.  Centrally they diminish sympathetic 
outflow by actions in the brainstem and spinal cord.  Peripherally, they 
stimulate classical presynaptic auto inhibitory α2 adrenergic receptors to 
decrease norepinephrine release. 
 
6.  GASTROINTESTINAL SYSTEM 
 
  Hyposalivation is one of the advantages of Clonidine as a 
premedicant.  Clonidine is also supposed to prevent intestinal electrolyte 
and water secretion in the large bowel. 
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7.  RENAL SYSTEM 
 
Clonidine induces diuresis by: 
 
(i)  Inhibition of Anti Diuretic Hormone (ADH) release. 
(ii)  Antagonism of the renal tubular action of ADH. 
(iii)  Increase in the Glomerular Filtration Rate (GFR). 
(iv)  Release of Atrial Natriuretic Factor. 
 
8.  HAEMATOLOGICAL SYSTEM 
 
  Clonidine induces platelet aggregation.  It also enhances the platelet 
aggregatory effects of other drugs. 
 
CLINICAL USES 
 
  The advantages of Clonidine over other adjuvants used in general 
anaesthesia and regional anaesthesia are: 
 
(i)  Lack of significant respiratory depression 
(ii)  Low abuse potential 
(iii)  Ability to rapidly reverse therapeutic and pharmacological effects 
with specific α2 antagonists. 
(iv)  Preservation of haemodynamic stability 
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(v)  Induced hypotension 
(vi)  Limits the use of potentially toxic anaesthetic adjuvant agents. 
(vii)  Preservation of renal function in the presence of insult 
(viii)  Limits the increase of Intra-Cranial Pressure (ICP) and Intra-Ocular 
Pressure (IOP). 
(ix)  Decrease of narcotic induced muscle rigidity. 
(x)  Bronchodilatation 
 
The disadvantages of Clonidine over other adjuvants include:  
 
(i)  Dry mouth 
(ii)  Sedation / Drowsiness 
(iii)  Bradycardia and 
(iv)  Hypotension. 
(v)  Should be used with caution in patients with severe coronary 
insufficiency, conduction disturbances, recent myocardial infarction, 
cerebrovascular disease and chronic renal failure. 
(vi)  Clonidine may potentiate the CNS depressive effects of alcohol, 
barbiturates or other sedating drugs. If a patient receiving Clonidine 
is also taking tricyclic antidepressants, the hypotensive effects of 
Clonidine may be reduced necessitating an increase in the Clonidine 
dose. 
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(vii)  Due to the additive effect such as bradycardia and heart blocks 
caution is warranted in patients receiving Clonidine with drugs like 
Digitalis, Calcium Channel Blockers and Beta Blockers. 
 
USES OF ORAL CLONIDINE IN GENERAL ANAESTHESIA  
 
1. Pre – Medication 
 
 As a pre-medicant 90-120 minutes prior to induction produces good 
sedation, maintains cardiovascular stability intraoperatively without 
respiratory depression. 
 
  Clonidine decreases intraocular pressure both before and during 
surgery. 
 
  Combination of oral and transdermal Clonidine maintains the 
plasma concentration of Clonidine at therapeutic levels to provide greater 
haemodynamic stability. 
 
2. Intra-operative Use 
 
  The major advantage over other general anaesthetic or supplements 
is providing haemodynamic stability.  Increases in blood pressure and heart 
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rate during tracheal intubation and surgical stress are blunted or abolished 
by Clonidine. 
 
  Clonidine induced sedation is counterbalanced by reduced 
requirement of other general anaesthetics and therefore the recovery 
time is actually reduced. 
 
  Clonidine may diminish myocardial ischaemia intra and post-
operatively after a single dose, which is beneficial in high risk patients. 
 
  Intrathecal Clonidine (150mcg) potentiates  local anaesthetic agents. 
It prolongs spinal anaesthesia with Bupivacaine in elderly patients 
undergoing orthopaedic surgery. 
 
  Postoperative administration of Extradural Clonidine produces 
effective analgesia in a dose dependant fashion in patients after knee 
arthroplasty or abdominal surgery. 
 
  Systemic Clonidine for postoperative analgesia in the dose of 
5μg/kg intramuscularly is very effective. 
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THERAPEUTIC USE OF CLONIDINE  
 
1.  Antihypertensive agent  
 Clonidine reduces blood pressure in all forms of hypertension with 
acute and chronic administration.  Although normally administered 
orally a cutaneous patch has also been used.  It is enhanced with the 
addition of a diuretic. In patients with renal failure, renovascular 
hypertension and pheochromocytoma, Clonidine is an effective 
hypotensive agent which does not further impair renal function. It 
can also be used for blood pressure control in patients with 
hypertension in pregnancy with satisfactory maternal and fetal 
outcome. 
 
2. Migraine prophylaxis 
  Clonidine has been used in doses of 50-150 μg daily in the 
prophylaxis of migraine. Reduction of vascular reactivity has been 
proposed to explain the role of Clonidine in migraine.  
 
3. Opiate withdrawal syndrome 
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 Clonidine hydrochloride has been used to reduce withdrawal 
symptoms following cessation of opiates, alcohol, benzodiazepines, 
and cigarette smoking.   
4. Glaucoma 
 Topical solutions of Clonidine hydrochloride 0.125 – 0.5% reduces 
intraocular pressure in patients with open-angle glaucoma.  
 
5. Anaesthesia  
 Clonidine has been used as an adjunct to local and general 
anaesthesia.   
 
6. Growth hormone screening test 
 Clonidine as a single oral dose has been used in the out-patient 
setting as a provocative test of growth hormone secretion in children 
with short stature.  The optimal dose is 100μg/m2 which produces a 
7-fold rise in HGH plasma concentration at 60 mins post dosing.  
 
7. Diagnosis of pheochromocytoma 
 The basis of this test is the ability of Clonidine to inhibit the release 
of norepinephrine from sympathetic neurons but not from 
pheochromocytoma cells. Compared to other pharmacological tests 
for pheochromocytoma (histamine, glucagons, or tyramine 
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provocation) Clonidine has the advantage of reducing rather than 
increasing blood pressure.  
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8. Psychiatric disorders 
 In Gilles de la Tourette’s syndrome, Clonidine appears to have some 
effect in improving motor and phonic tics and associated behaviour 
problems.   
 
9. Menopausal symptoms 
 Clonidine in a dose up to 200 μg daily has been shown to reduce 
menopausal hot flushes by about 60%.  
 
10. Chronic diarrhea  
 Clonidine has been reported to be effective in controlling diarrhea in 
diabetic patients with autonomic neuropathy. Stimulation of α2-
adrenoceptors on enterocytes, promoting fluid and electrolyte 
absorption and inhibiting anion secretion, has been proposed as the 
mechanism of action of Clonidine. 
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FESS SURGERY22 
 
Functional endoscopic sinus surgery (FESS) is a minimally invasive 
technique in which sinus air cells and sinus ostia are opened under direct 
visualization.  The goal of this procedure is to restore sinus ventilation and 
the normal function of the nasal sinuses. 
 
CANDIDATES FOR SINUS SURGERY 
 
  FESS (like any sinus surgery) is most successful in patients who 
have recurrent acute or chronic infective sinusitis.  Patients in whom the 
predominant symptoms are pain over the maxillary sinus and nasal 
blockage usually respond well.  The sense of smell often improves after 
FESS surgery.  
 
  A CT scan before FESS is mandatory to identify the patient’s 
ethmoid anatomy and its relationship to the skull base and orbit.  CT scan 
defines  the extent of the disease, as well as any underlying anatomic 
abnormalities that may predispose a patient to sinusitis.  
 
  Patient selection therefore involves a thorough history and physical 
examination, a trial with medical treatment and finally, CT scanning.  The 
result is a highly selected group of patients who can expect an 
improvement of up to 90 percent in their symptoms.  
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Anatomy of Nasal Turbinates 
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SURGICAL TECHNIQUE 
 
  After suitable vasoconstriction using cocaine or ephedrine, the 
middle turbinate is identified.  This is the most important landmark for the 
procedure.  On the lateral wall of the nose at the level of the anterior end of 
the middle turbinate lies the uncinate process.  This is removed, exposing 
the ethmoid bulla and the opening called the hiatus semilunaris, into which 
the frontal and maxillary sinuses drain.  
 
  The anterior ethmoid air cells are then opened, allowing better 
ventilation but leaving the bone covered with mucosa.  Following this, the 
maxillary ostium is inspected and, if obstructed, opened by means of a 
middle meatal antrostomy.  This minimal surgery will often be sufficient to 
improve the function of the osteomeatal complex and therefore to provide 
better ventilation of the maxillary, ethmoid and frontal sinuses.  
 
  Occasionally the CT scan shows disease in the posterior ethmoids 
and the sphenoid sinus.  It is then necessary to continue further into these 
sinuses.  However, in most of the cases, the inflammation is confined to 
the osteomeatal complex and the anterior ethmoids.  
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POSTOPERATIVE CARE 
 
  Postoperatively, a nasal pack is applied over both the nostrils to 
reduce the bleeding. Patient is advised to breathe orally. The nasal pack is 
usually removed after 12-20 hours. It is important to keep the nose as free 
from build-up of crusts as possible.  Nasal cleansing is performed two or 
three times a week by the surgeon and simple nasal douching carried out 
several times a day by the patient. Normal function usually returns within 
one to two months.  
 
OUTCOME 
 
  The results after FESS are good, with most studies reporting an 80 
to 90 percent rate of success.  Good results also have been obtained in 
patients who have had previous sinus surgery.  
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REVIEW OF LITERATURE 
 
 
 Literature reviewed to analyse various agents administered during 
FESS surgery to reduce intra operative bleeding and thereby providing a 
clear surgical field and also the effectiveness of oral Clonidine as a 
premedicant to reduce intraoperative bleeding. 
 
 
*  In 1987, WOODCOCK ET AL31, conducted a study with clonidine 
premedication for isoflurane induced hypotension,the 
sympathoadrenal responses and a computer controlled assessment of 
the vapor requirements. It was found that the mean concentration 
of 1.4% isoflurane was required to maintain hypotension in the 
clonidine group compared to 2.3% of the control group. 
 
* In 1992, REIGLE ET AL23, conducted a study with three different 
vasoconstricting agents in 57 patients undergoing FESS surgery 
(oxymetazoline Hcl 0.05%, phenylephrine Hcl 0.25% and cocaine 
4%). The HR and BP was recorded every 5 to 10 minutes. It was 
found that 0.05% oxymetazoline is the preferred vasoconstrictor 
in patients undergoing FESS surgery. 
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*  In 1992, WELFRINGER ET AL30, studied the effects of clonidine 
premedication and isoflurane anaesthesia to reduce bleeding in 
otologic surgery in 77 patients. The comparative assessment of 
bloodless surgical field quality was in favour of the clonidine 
group. 
 
 
*  In 1995, ANDRE ET AL2, compared sodium nitroprusside (SNP) 
with esmolol in 40 patients as the primary hypotensive agent. It was 
found that SNP induced hypotension was poor (due to the 
vasodilatory effects and tachycardia) when compared with 
esmolol, which was ideal. (due to unopposed α adrenoceptor 
effect on the mucous vasculature). 
 
*  In 1996, FRIEDMAN ET AL7, conducted a study of topical 
bupivacaine for post operative pain in patients who had undergone 
FESS in 57 patients 
 
*  In 1998 BARRERA ET AL3, studied the perioperative analgesic 
effect of clonidine administered by the systemic and epidural route 
in patients undergoing abdominal hysterectomy. He concluded that 
the epidural route provided post operative analgesia suggesting a 
spinal site for the analgesic action. 
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*  In 2000, SUNG.C.S.ET AL26, studied the endocrine correlates of the 
haemodynamic changes induced by the CO2 pnuemoperitonium and 
its attenuation by oral clonidine as premedication. It was concluded 
that vasopressin and catecholamine, which mediated the 
increase in SVR was significantly reduced before 
pnuemoperitonium by oral clonidine during laparascopic 
surgery. 
 
*  In 2001,MARCHAL ET AL19, conducted a study on clonidine and 
decreases in intraoperative bleeding in middle ear microsurgery, in 
40 patients of which 21 received clonidine 90 minutes prior to 
surgery and 19 received placebo. The end point of anaesthetic 
management was maintenance of hypotension for a bloodless 
surgical field. It was concluded that clonidine reduced bleeding 
in middle ear microsurgery, attenuated hyperdynamic response 
to tracheal intubation and reduced isoflurane, fentany and 
urapidil requirements for controlled hypotension. 
 
*  In 2005, JABALMELI ET AL13, studied oral clonidine to reduce 
intra-operative bleeding in patients undergoing FESS surgery in 113 
patients (ASA 1 and 2). 52 patients received oral clonidine 90 
minutes prior to surgery and 61 received placebo. It was seen that 
clonidine reduced bleeding in FESS surgery and also reduced 
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fentanyl and hydralazine requirements for controlling 
hypotension. 
 
* In 2003, P. Mandal et. al experimented Isoflurane Anaesthesia for 
Functional Endoscopic Sinus Surgery, Thirty patients who 
underwent functional endoscopic sinus surgery (FESS) under 
general anaesthesia were provided hypotensive anaesthesia (Group 
I) with isoflurane to facilitate bloodless operative field. The MAP 
was maintained between 55-60 mmHg. Another group of similar 30 
patients were provided normotensive anaesthesia and acted as 
control (Group II). The mean duration (min.) of surgical procedure 
was lesser (p <0.05) in group I compared to group II.Similarly mean 
blood loss (ml) was considerably lower in group I   
 
* In 2004, G. Tirelli et al., studied Total Intravenous Anaesthesia in 
endoscopic Sinus-Nasal Surgery, using Remifentanyl and Propofol, 
or Inhaled using Isoflurane and Fentanyl. It was concluded that the 
Hypotensive effect of total intravenous anaesthesia and of Isoflurane 
and Fentanyl was equivalent, but only total intravenous anaesthesia 
was effective in reducing bleeding during FESS surgery.  
 
* In 2006, N.M. Elsharnouby et. Al studied Magnesium sulphate as a 
technique of hypotensive anaesthesia in FESS surgery Magnesium 
sulphate led to a reduction in arterial pressure, heart rate, blood loss 
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and duration of surgery. Furthermore, magnesium infusion alters 
anaesthetic dose requirements and emergence time. 
 
* In 2006, Jian-jun Yang et al, studied Epinephrine Infiltration on 
Nasal 
Field Causes Significant Hemodynamic Changes: Hypotension 
Episode Monitored by Impedance-cardiography under General 
Anesthesia, According to the results of the study, it was concluded 
that local infiltration with low dose epinephrine causesd marked 
hemodynamic changes including decrease in MAP and SVRI, and 
increase in HR, CI and ACI during FESS under general anesthesia. 
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MATERIALS AND METHODS 
 
  Sixty ASA Class I patients of both sexes between the age of 20 – 40 
years weighing between 40 – 65kgs, who were scheduled for elective 
Endoscopic  Nasal Sinus Surgery under General Anaesthesia  at 
Government Stanley  Hospital were selected for this study.  
 
This study was designed as prospective randomized comparative 
study. After receiving the institutional ethical committee approval and 
informed consent, the patients were allocated into two groups, the 
clonidine group (C) and the placebo group (P), each group comprising of 
thirty patients respectively.  
 
INCLUSION CRITERIA 
 
(i)  ASA PS I. 
(ii)  Age 20 – 40 years. 
(iii)  Weight between 40-65 kgs. 
(iv)  Patients undergoing FESS surgery. 
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EXCLUSION CRITERIA 
 
(i) Hypertension/ Ischaemic Heart Disease (IHD)/ Rheumatic heart 
disease. 
(ii) Diabetes Mellitus. 
(iii) Obesity  
(iv) Anticipated difficult airway 
(v) Sinus bradycardia / heart blocks / conduction defects 
(vi) Patients on Antipsychotics 
(vii) Patients on Digitalis, Calcium Channel Blockers and β-blockers  
(viii) H/o CerebroVascular Disease (CVA) 
(ix) Chronic renal disease with increased renal parameters. 
(x)  Preoperative Hypotension 
(xi) Patient refusal. 
 
All the patients were informed about the procedure and written 
consent obtained.  
 
Prof. of ENT Department was informed about the study and his prior 
permission was obtained. 
 
  This study was carried out in the theatre where facilities for Induced 
Hypotension and Resuscitation were available. 
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PROCEDURE 
 
PRE-OPERATIVE ASSESSMENT  
 
All the patients were examined prior to surgery. Routine Clinical 
Examination, Biochemistry Tests, Electrocardiogram and Chest X-Ray 
were examined thoroughly for the conduct of anaesthesia.  Only those 
patients in the ASA Class I were taken into this study.  
 
  NPO duration was eight hours and fluid replacement during Intra 
operative period was according to the 4 – 2 –1 rule.  
 
  Baseline Heart Rate and Blood Pressure both Systolic and Diastolic 
were recorded prior to pre-medication in both the study groups. 
 
PRE-MEDICATION 
 
          Patients were randomly allocated into two groups, Group C 
(Clonidine) and Group P (Placebo). 
 
  Group C patients received oral Clonidine 5 μg/kg with sips of water 
90 minutes before surgery. This period ensures maximum plasma 
concentration after oral ingestion of the drug.  Group P patients received 
placebo drug. All the patients received a nasal packing 2% xylocaine and 
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1:200000 of adrenaline in order to shrink the nasal mucosal vessels. 
Injection Glycopyrolate 0.2 mg i.m was given as an anti-sialogogue 45 
minutes prior to Induction. 
 
  Patients were assessed for level of sedation at 30 minutes, 60 
minutes and 90 minutes after pre-medication.  The following score was 
used to assess the Degree of Sedation. 
Grade 1:  Awake and alert patient. 
Grade 2:  Awake and calm lying down quality. 
Grade 3:  Drowsy, arousable on oral commands. 
Grade 4:  Drowsy, arousable on mild physical stimuli. 
Grade 5:  Drowsy, arousable on vigorous physical stimuli only. 
 
  90 minutes after pre-medication the patients were shifted to the 
operating theatre.  Intravenous cannulation was secured and a maintenance 
infusion of 5% Glucose Normal Saline was started and infusion adjusted at 
a rate of 8 to 10ml/kg/hour.   
 
Monitors used were:  
 
(i)  Electrocardiographic leads,  
(ii) Non-invasive blood pressure – sphygmomanometer cuff, and  
(iii) Pulse oximetry. 
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CONDUCT OF ANAESTHESIA 
 
  Pre-induction Heart Rate and Blood Pressure both Systolic, 
Diastolic and MAP were recorded.  After Pre-oxygenation with 100% 
oxygen for 3 minutes, anaesthesia was induced with Thiopental sodium 
5mg/kg, Fentanyl 2μg/kg and Vecuronium Bromide 0.1mg/kg.  Then 
laryngoscopy was performed and the trachea was intubated after 3 minutes 
of mask ventilation with 100% oxygen. In all patients ventilation was 
controlled manually. Anaesthesia was maintained with Nitrous oxide and 
oxygen (2:1 ratio) and Halothane 0.25 volume %. Vecuronium top-up 
doses were given as and when required. 
 
  Thereafter the Heart Rate and Blood Pressure were measured at 1 
and 5 minutes after induction of anaesthesia and through every 5 minutes 
for the first 30 minutes and then every 15 minutes thereafter intra-
operatively. 
 
  To maintain hypotension for producing a bloodless surgical field, 
mean arterial pressure was proposed to be 75 mm Hg.  Halothane was 
administered with a minimum of 0.25volume % in both the Groups and 
later given in escalating doses to a maximum of 1 volume % if necessary.  
If unsuccessful, Intravenous Fentanyl bolus of 2 μg/kg was added.  When 
both the drugs failed to provide the desired target, Injection Nitroglycerin 
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diluted to a concentration of 100μg/ml and given as a continuous infusion 
(0.5-10 μg/min). Intraoperative bleeding was assessed according to the 
Bleeding severity score given below: (Jabalmeli Et AL). 
 
0 –  No bleeding. 
1 –  Slight bleeding, no suction of blood required. 
2 –  Slight bleeding, occasional suctioning required, surgical field not 
threatened. 
3 –  Slight bleeding, frequent suctioning required, bleeding 
threatened surgical field a few seconds after suction was 
removed.  
4 –  Moderate bleeding, frequent suctioning required.  Bleeding 
threatened surgical field directly after suctioning was removed. 
5 –  Severe bleeding, constant suction required.  Bleeding appeared 
faster than could be removed by suction surgical field severely 
threatened and surgery was not possible. 
 
Surgeons remarks regarding the field of surgery was also noted. 
 
Injection Atropine 0.6mg was given in titrated doses intravenously if 
the heart rate went below 60 beats/minute.  Patients with a MAP below 
65mmHg were treated with Intravenous supplements of Inj. Ephedrine 
6mg and infusion of Intra Venous (IV) fluids. 
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REVERSAL OF RESIDUAL PARALYSIS AND RECOVERY 
 
  Patients were reversed with Injection Neostigmine 0.05mg/kg body 
weight and Injection Atropine 0.02mg/kg body weight at the end of 
surgery. 
 
  Extubation was done when there was a good gag reflex to 
oropharyngeal stimulation by the suctioning catheter, adequate tidal 
volume as evidenced by the chest movements and reservoir bag. 
 
  The adequacy of return of motor power could not be tested clinically 
in the clonidine group as the majority of these patients were well sedated. 
 
The patients were shifted to the recovery room and supplemented 
with oxygen through ventimask.  They were observed for 60 minutes 
during which the vital parameters like the Heart Rate, Blood Pressure, 
SpO2 and Respiratory Rate were monitored.  They were subsequently 
shifted to the post-operative ward and their vitals were continuously 
monitored and recorded at 2 hours and 4 hours.  Patients were also 
assessed for post-operative analgesia at 5 minutes, 30 minutes, 2 hours and 
4 hours after extubation.  Analgesia was assessed as follows:  
 
Grade 1:  Patient restless and screaming with pain. 
Grade 2:  Patient complaining of severe pain and demands relief. 
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Grade 3:  Patient comfortable complains of pain on questioning. 
Grade 4:  No complaint of pain. 
 
  The nursing staff were instructed to give Injection Pentazocine 
0.5mg/kg body weight intramuscularly when the patient complained of 
pain in the post-operative period with the grading of 1 or 2. 
 
  All the patients were observed for 24 hours after surgery for any side 
effects like nausea, vomiting and dizziness. 
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OBSERVATIONS 
 
STATISTICS AND ANALYSIS  
 
  Sample size of 30 per group was taken for this study.  Data was 
expressed as mean ± standard deviation (SD) or absolute values.  
Qualitative data were compared with the Chi square test and fisher’s exact 
test.  Quantitative variables were compared with the student ‘t’ test.  The 
level of statistical significance was set at p <0.05. 
 
DEMOGRAPHIC PROFILE  
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The mean age in Group C was 26.866 ± 4.400 SD and in the Group 
P it was 26.366 ± 4.0809 SD (p = 0.649). 
 
The mean weight in Group C was 53 ± 6.812 SD  
 
The mean weight in Group P was 51.13 ± 5.475 SD (p = 0.246) 
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Sex distribution in each group was equal Males  = 17 
       Female  = 13 
 
Thus the demographic profile was comparable between the two 
groups. p value not significant.  
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Group P (90 Mins)
Grade 1
100%
SEDATION 
 
  
 
 
 
 
 
 
SEDATION SCORE 
30 mins 60 mins 90 mins 
Score Grade of sedation and Anxiolysis Group  
C 
Group 
P 
Group  
C 
Group  
P 
Group  
C 
Group 
P 
- - 
1 Awake & Alert 4 (13.33%) 30 (100%)
  
30 (100 %) 
  
30 (100%)
- - - 2 Awake, Calm, Lying Quietly 25 (83.33%)   4 (13.33 %)   3 (10%)   
- - - 3 Drowsy Arousable on Oral Commands 1 (3.33 %)   26 (86.67%)   23 (76.67%)   
- - - - - 4 Drowsy Arousable on Mild Physical Stimuli         4 (13.33 %)   
5 
Drowsy Arousable on 
Vigorous Physical 
Stimuli Only 
- - - - - - 
 
 
 All the patients were alert at the end of 90 minutes in Group P. 
 
 In Group C it was found that 23 (76.67%) patients were in the Grade 
3 and 4 (13.33%) patients in the Grade 4 of the sedation score at end of 90 
minutes.  
Group C (90 Mins)
Grade 
2
10%
Grade 
1
0%
Grade 
4
13%
Grade 
3
77%
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INTRA-OPERATIVE DRUG REQUIREMENT 
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30 Mins. Sl. No. Drug Group C Group P 
1 Fentanyl 2 (6.67%) 9 (30.00%) 
2 Halothane   
 0. 5 V% 2 (6.67%) 5 (16.67%) 
 0.75 V% 0 15 (50.00%)
 
 
1.0 V% 
 0 10 (33.33%)
3 NTG 1 (3.33%) 6 (20.00%) 
4 Atropine 1 (3.33%) 0 
5 Ephedrine 1 (3.33%) 0 
 
(i)  9 (30%) of patients in Group P needed top up doses of Fentanyl 
when compared to 2 (6.66%) of Group C.  
 
(ii)  It is hereby seen that a significantly higher consumption of 
Halothane 0.75 volume % almost 15 (50%) of patients in Group P 
66 
and 10 (33%) patients in Group P needed 1 V% of Halothane.  
Where as only 2 patients in the Clonidine Group required 0.5 V% of 
Halothane. 
 
(iii)  6 (20%) of patients in Group P needed NTG infusion (0.1 mg/kg). 
While only 1 (3.33%) patient in Group C needed the same.  
 
COMPLICATIONS WITH CLONIDINE  
 
 Bradycardia with a Heart Rate < 60 /min. occurred in 1 patient 
necessitating the use of Injection Atropine 0.6 mg IV.  1 patient developed 
hypotension with MAP <65 mm Hg and corrected with IV fluids and 
Injection Ephedrine 6 mg IV in titrated doses.  
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HAEMODYNAMIC PARAMETERS 
Heart Rate 
Sl. 
No. Time of observation   
HR      
(Bt/min) SD p 
1 Group C 81.166 4.026 0.154 
  
Baseline 
Group P 79.633 4.213   
2 Group C 72.8 5.821 0.000 
  
Preinduction 
Group P 91.6 3.45   
3 Group C 75.566 6.463 0.000 
  
At Scopy 
Group P 95.098 18.422   
4 Group C 76.601 6.499 0.000 
  
One minute after 
intubation Group P 94.223 2.721   
5 Group C 80.333 7.871 0.1308 
  
Five minute after 
intubation Group P 85.396 16.294   
6 Group C 69.66 14.406 0.63 (NS)
  
During extubation 
Group P 85.232 18.436   
7 Group C 72.1 10.121 0.000 
  
One minute after 
extubation Group P 89.03 6.206   
8 Group C 75.533 11.578 0.001 
  
Five minute after 
extubation Group P 84.733 5.051   
9 Group C 73.066 15.097 0.052 
  
Thirty minute after 
extubation Group P 78.795 4.727   
10 Group C 78.333 10.346 0.94 (NS)
  
Two hours after 
extubation Group P 78.13 124.3   
11 Group C 80.366 8.176 0.0268 
  
Four hours after 
extubation Group P 76.466 4.651   
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SYSTOLIC BLOOD PRESSURE (SBP) 
Sl. 
No. Time of observation   SAP SD p 
1 Group C 123.33 7.111 0.253 
  
Baseline 
Group P 121.33 6.2881   
2 Group C 106.766 5.864 0.000 
  
Preinduction 
Group P 128 6.643   
3 Group C 112 7.282 0.000 
  
At Scopy 
Group P 133.666 6.149   
4 Group C 112.366 6.609 0.000 
  
One minute after 
intubation Group P 130.733 3.58   
5 Group C 115.766 8.475 0.000 
  
Five minute after 
intubation Group P 125.2 4.859   
6 Group C 102.133 9.449 0.0011 
  
During extubation 
Group P 110.6 6.083   
7 Group C 107.266 10.175 0.006 
  
One minute after 
extubation Group P 113 4.347   
8 Group C 110.966 10.001 0.748 
  
Five minute after 
extubation Group P 111.666 6.477   
9 Group C 104.566 9.859 0.001 
  
Thirty minute after 
extubation Group P 113.33 6.006   
10 Group C 115.066 6.781 0.636 
  
Two hours after 
extubation Group P 114.333 5.04   
11 Group C 118 7.1438 0.356 
  
Four hours after 
extubation Group P 116.337 6.689   
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DIASTOLIC BLOOD PRESSURE (DBP) 
Sl. 
No. Time of observation   DAP SD p 
1 Group C 82 6.102 0.015 
  
Baseline 
Group P 77.66 7.279   
2 Group C 67.766 5.076 0.000 
  
Preinduction 
Group P 84.333 6.26   
3 Group C 73.333 5.64 0.000 
  
At Scopy 
Group P 91.933 4.346   
4 Group C 76.9 6.676 0.000 
  
One minute after 
intubation 
Group P 117.9 151.701 Wilcoxan sum test 
5 Group C 80.233 8.81 0.011 
  
Five minute after 
intubation Group P 85.2 5.498   
6 Group C 68.733 7.886 0.0002 
  
During extubation 
Group P 76.533 4.868   
7 Group C 68.2 10.626 0.000 
  
One minute after 
extubation Group P 79.933 5.595   
8 Group C 68.966 10.063 0.000 
  
Five minute after 
extubation Group P 79.533 5.001   
9 Group C 66.533 7.682 0.000 
  
Thirty minute after 
extubation Group P 77.666 4.301   
10 Group C 75.8666 7.295 0.076 
  
Two hours after 
extubation Group P 78.666 4.341   
11 Group C 80 5.872 0.35 
  
Four hours after 
extubation Group P 81.333 5.074 (NS) 
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MEAN ARTERIAL PRESSURE (MAP) 
Sl. 
No. Time of observation   MAP SD p 
1 Group C 95.77 5.174 0.01 
  
Baseline 
Group P 92.22 5.276   
2 Group C 67.766 5.076 0.000 
  
Preinduction 
Group P 84.333 6.26   
3 Group C 73.333 5.64 0.000 
  
At Scopy 
Group P 91.933 4.346   
4 Group C 76.9 6.676 0.000 
  
One minute after 
intubation 
Group P 117.9 151.7 Wilcoxan sum test 
5 Group C 92.077 8.342 0.003 
  
Five minute after 
intubation Group P 98.53 4.261   
6 Group C 79.866 8.102 0.000 
  
During extubation 
Group P 87.88 3.408   
7 Group C 81.222 10.017 0.000 
  
One minute after 
extubation Group P 90.955 3.833   
8 Group C 82.966 9.47 0.0003 
  
Five minute after 
extubation Group P 90.243 4.633   
9 Group C 79.21 7.726 0.000 
  
Thirty minute after 
extubation Group P 89.555 3.358   
10 Group C 88.932 6.313 0.2168 
  
Two hours after 
extubation Group P 90.554 3.284   
11 Group C 92.666 4.581 0.7722 
  
Four hours after 
extubation Group P 93 4.321 (NS) 
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HEART RATE
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A Baseline G During extubation 
B Preinduction H One minute after extubation 
C At Scopy I Five minute after extubation 
D One minute after intubation J Thirty minute after extubation 
E Five minute after intubation K Two hours after extubation 
F Average intra-operative value L Four hours after extubation 
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DBP
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F Average intra-operative value L Four hours after extubation 
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Intra-Operative Haemodynamic Parameters
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CARDIOVASCULAR PARAMETERS 
 
Mean values of haemodynamic parameters (HR, SAP, DAP, MAP) 
were taken as pre induction, at scopy 1 and 5 mins thereafter, intra-
operatively, at extubation, 1 min, 5 mins, 30 mins,  2 hours and 4 hours 
thereafter.  
 
INTRA-OPERATIVE PARAMETERS   
 
Haemodynamic stability was remarkable with Group C as seen by 
the comparisons with Group P.  The equivalent stability was maintained in 
Group P with additional analgesic top-ups, Halothane 0.5-1.0 Vol% and 
NTG infusion.  
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 The pressor response to both intubation and extubation was blunted 
in the clonidine group. 
 
Mean duration of surgery  
 
  
  
   p = 0.33 [NS]  
 
 
Group  Minutes SD 
Clonidine  53.33 ± 17.137 
Placebo 57.166 ± 12.844 
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BLEEDING SEVERITY SCORE 
 
Score Bleeding severity score Group C Group P 
0 No Bleeding - - 
1 Slight Bleeding, No suctioning of blood required 12 (40%) 6 (20%) 
2 Slight Bleeding, Occasional suctioning of blood required.  Surgical field not threatened 14 (46.67%) 
14 
(46.67%) 
3 
Slight Bleeding, frequent suctioning of blood 
required.  Bleeding threatened surgical field a few 
seconds after suction was removed. 
4 (13.33%) 7 (23.33%) 
4 
Moderate bleeding, frequent suctioning required.  
Bleeding threatened surgical field directly after 
suction was removed. 
- 3 (10%) 
5 
Severe bleeding, constant suctioning required.  
Bleeding appeared faster than could be removed 
by suction.  Surgical field severely threatened and 
surgery not possible. 
- - 
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 Bleeding graded on the basis of the severity score 3 & 4 was found 
to be higher in the Placebo Group (7 Patients with a score of 3 and 3 
Patients with a score of 4). 
 
 Frequency of bleeding severity score of 1 in the Clonidine Group 
was significantly greater than that of Placebo Group, thus indicating that 
bleeding was considerably less in the Clonidine Group. 
 
 However, an equal number of patients in both Groups had a 
score of 2.  This was attained by the use of higher concentration of 
Halothane and NTG infusions in the Group P. 
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RESPIRATORY PARAMETERS AND SpO2  
POST OPERATIVELY 
 
 
All the patients were observed for 24 hours post operatively and it 
was found that there was no respiratory depression in both the groups. The 
patients in both groups had a stable cardiovascular status in the post-
operative period.   
 
SIDE EFFECTS  
 
Group P: 3 Patients had nausea and 5 patients complained of dizziness 
post operatively.  
Group C: Only 1 Patient had nausea and 2 patients had symptoms of 
dizziness.  
 
 They were treated symptomatically.  
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POST OPERATIVE ANALGESIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 (90%) patients out of 30 had no complaint of pain till 4 hours 
following surgery in the clonidine group.  
 
15 (50%) out of 30 patients had a grade 3 while 9 (17%) patients 
demanded relief in the placebo group after 2 hours post operatively. 
Group C - 2 Hrs.
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DISCUSSION 
 
Controlled hypotension is a technique used to reduce bleeding in 
patients undergoing middle ear surgery, nasal surgery, neuro surgery, 
orthopaedic surgery, head and neck surgery and plastic surgery.  During 
FESS surgery the single and most common complication is excessive 
bleeding15.   
 
Various studies have been done to enable a reduction in bleeding 
during FESS surgery by using various vasoconstricting agents like 
Oxymetazoline Hcl (0.05%), Phenylephrine Hcl (0.25%) and cocaine 4%23 
and  by the use of Isoflurane30. SNP and Esmolol were also experimented 
as primary hypotensive agents2.  
 
 Clonidine an α2 agonist and a potent suppressor of sympathoadrenal 
activity was given orally 90 minutes prior to surgery, in an aim to produce 
hypotension thereby reducing intra-operative bleeding and the duration of 
surgery.  The need for other hypotensive agents was observed to be 
reduced with Clonidine.  All the patients had a very constant and stable 
Haemodynamic status intra-operatively20,21,26,27. Clonidine   suppresses 
central noradrenergic activity with secondary attenuation of perioperative 
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hemodynamic fluctuations and stress response as supported by studies 
done by Pouttu et al20 and Quintin et al21.  
 
In this study, the effects of oral Clonidine (5 μg/kg) on intra-
operative bleeding in Endoscopic Nasal Sinus surgery was studied.  
Bleeding severity score of 3 and 4 was seen to be higher in the Placebo 
Group than with Clonidine. These findings were similar to that of 
Marchal et al19 and Welfringer et al30 studies.  
 
 The Induced Hypotension effect by oral Clonidine directly attributed 
to reduced bleeding and a good surgical field.  Hypotension was 
produced in the Placebo Group using higher concentrations of 
Halothane and NTG infusion. There was a statistically significant 
difference in the Halothane requirement of both the Clonidine and Placebo 
Group.  This was in concert with the study of Marchal et al who observed 
that the intra-operative consumption of Isoflurane was less in patients 
premedicated with Clonidine than in control patients undergoing middle 
ear micro surgery.  In this study 28 patients belonging to the Clonidine 
Group attained a MAP of 75 mm Hg with 0.25 V% of Halothane whereas 
25 patients in the Placebo Group required concentrations > 0.5 V%.  6 
Patients in the Placebo Group were started on NTG infusion to reduce the 
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MAP.  This is also in concert with Marchal et al study on lowered doses of 
Urapidil to decrease blood pressure in patients given oral Clonidine.  
 
 With Clonidine, Fentanyl requirement was also significantly reduced 
when compared with the Placebo Group.  This is attributed to the 
Pharmacological properties of Clonidine which includes analgesia.  
 
 Patients who were given oral Clonidine as a premedicant were well 
sedated and calm pre-operatively, when compared to the patients in the 
Placebo Group who were all alert and required additional analgesic top ups 
and higher concentrations of Halothane.  
 
 Extubation was smooth in all the patients of the Clonidine group 
who were sedated but arousable.  Patients in the Placebo Group were 
sedated and drowsy in the post-operative period thereby requiring a longer 
observation in the recovery room. 
 
COMPLICATIONS DUE TO THE SIDE EFFECTS OF CLONIDINE 
 
(i) Bradycardia with a heart rate < 60 /min was encountered in 1 patient 
and 1 patient developed hypotension with a MAP <65mmHG. 
(ii)  Only 1 patient had nausea and 2 patients had dizziness. 
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(iii)  It was seen that the Heart rate and Blood Pressure returned to 
baseline levels only until after 4 hours postoperatively, emphasizing 
the need for stringent monitoring care in these patients. 
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SUMMARY  
 
 The advantages of Clonidine as premedicant can be summarized as 
follows: 
 
* Excellent Sedation and Anxiolysis 
* Attenuation of stress response to laryngoscopy and intubation. 
* Maintenance of intraoperative cardiovascular stability by 
maintaining Heart Rate and Blood Pressure.  
* Good intraoperative analgesia. 
* Postoperative Sedation and Analgesia. 
* Devoid of Respiratory depression. 
* Less distressing side effects like nausea and vomiting.  
* Easy administration.  
 
 Clonidine possesses certain limitations in its usage in patients with 
bradycardia, conduction disturbances and cardiovascular instability as it is 
likely to worsen the Cardiovascular status.  As it may cause excessive 
sedation, it is better to be avoided or used with caution in patients with 
airway obstruction, obesity and extremes of age.  
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 Clonidine at a dose of 5 μg/kg body weight with a ceiling dose of              
300 μg is tolerated well by the patients without major complications.  
 
 Premedication with oral Clonidine in FESS surgery greatly 
facilitated controlled hypotension with a clear surgical field which was 
greatly appreciated by the operating surgeon.  
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CONCLUSION  
 
  The present prospective randomized controlled study shows that 
Oral Clonidine premedication 90 minutes prior to surgery provides a 
considerable reduction in bleeding during Functional Endoscopic Sinus 
Surgery under General Anaesthesia (with 0.25V% Halothane 
supplementation).  It also reduces (almost negligible) the need for other 
hypotensive drugs to provide a clear field for surgery.  Therefore Oral 
Clonidine can be used as premedicant as well as a hypotensive agent for 
FESS surgery.  
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PROFORMA 
 
Name :    Age :   Years  Sex:  M /F  Weight :     
Kg 
 
Date :   I.P. No.:  Duration of surgery :      Minutes 
 
Pre-medication:  Dosage Time 
 
T. Clonidine  
 
Inj. Glycopyrrolate 0.2 mg im 
 
Sedation scoring : ______ 30 mts ______ 60 mts _____ 90 mts. 
 
Base Pre-induction : Heart Rate   : 
 
Blood Pressure  :  Systolic mmHg 
         Diastolic mmHg 
 
Response to Laryngoscopy and tracheal intubation  
 
Parameters At scopy and intubation 
1 Minute after 
intubation 
5 Minutes after 
intubation 
HR    
BP    
Systolic (mmHg)    
Diastolic (mmHg)    
 
Intra-operative hemodynamic monitoring   
 
At 5 min 
10 
mins 
15 
mins 
20 
mins 
25 
mins 
30 
mins 
45 
mins 
60 
mins 
75 
mins 
Bl.loss 
grading  
HR           
BP           
Systolic mmHg           
Diastolic mmHg           
 
Response to reversal and intubation 
 
 1 Minutes 5 Minutes 
HR   
BP   
Systolic mmHg   
Diastolic mmHg   
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Intra Operative Drug requirements  
 
Drugs Dose (mg) Frequency  
Injection Fentanyl   
Halothane    
NTG Infusion   
Injection Atropine   
Injection Ephedrne    
 
 
Post Operative Hemodynamic status, analgesia, respiratory status   
 
Parameters 30 mts 2 hrs. 4 hrs. 
HR    
BP    
SBP mmHg     
DBP mmHg    
Analgesic score     
Respiratory Rate    
Spo2    
Other observations    
Nausea     
Vomiting     
Dizziness    
Resp. depression.    
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